Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
343
resultados
Última actualización
03/08/2026 [08:30:00]
Resultados 150 a 175 de 343
Resumen de: CN122326739A
本发明公开了血清标志物miR‑206在制备阿尔茨海默病诊断产品中的应用，本发明首次将血清标志物miR‑206用于阿尔茨海默病的有效诊断与辅助诊断中，并且具有极高的诊断性能。本发明为开发稳定、可靠的阿尔茨海默病即时检测试剂盒或自动化化学发光检测系统等体外诊断产品奠定了技术与数据基础，具有推动阿尔茨海默病早期筛查、辅助诊断从依赖复杂影像和脑脊液检查向便捷、无创的血液检测转变的重大临床应用前景。
Resumen de: WO2025120373A1
Methods of determining the potency of a human neonatal Fc receptor (FcRn) antagonist composition in inhibiting the binding of human IgG to FcRn using a competition binding assay are provided. Kits for carrying out said methods, and methods of manufacturing a FcRn antagonist composition comprising said methods of determining potency are also provided.
Resumen de: CN122330416A
0001 本发明属于生物技术领域，公开了血清淀粉样P物质（SAP）作为生物标志物在制备诊断或预测射血分数保留型心力衰竭合并心房颤动（HFpEF合并AF）的产品中的应用。本发明通过构建HFpEF合并AF动物模型发现，SAP在动物模型中表达水平显著升高；在临床患者血浆样本中验证发现，HFpEF合并AF患者血浆中的SAP水平较对照组显著升高。因此，本发明通过对血浆中SAP进行定量检测，可实现对HFpEF合并AF的预测或诊断。
Resumen de: CN122325600A
本发明提供一种用于诊断阿尔茨海默症的抗体及其制备方法。申请人通过研究发现了几组抗体对，利用双抗夹心法检测p‑Tau217，亲和力和灵敏度高，对阿尔茨海默症的诊断具有十分积极的意义。
Resumen de: CN122325602A
本发明涉及免疫学技术领域，具体公开了一种抗Tau单克隆抗体及其应用，其重链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:1、2和3所示的氨基酸序列；且其轻链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:4、5和6所示的氨基酸序列。本发明提供的抗Tau单克隆抗体能够结合Tau蛋白N端投射区域，特异性识别Tau蛋白N端Thr95/Thr101磷酸化修饰位点，能用于人脑样本中Tau蛋白及其病理相关组分的免疫印迹检测，能用于转基因动物和人脑组织样本中Tau病理结构的组织学检测以及Tau蛋白相关疾病中的病理分期的研究。
Resumen de: CN122330436A
0001 本发明公开了一种外泌体检测方法，包括将生物样本与裂解液混合得到样本裂解液的步骤；所述裂解液与生物样本的体积比为1:1。使用本发明中的提取外泌体和直接裂解两种方法检测TSG101和PDCD6IP浓度，所得检测结果具有较高的一致性，即本方法在提高效率的同时还具有较高的准确性。
Resumen de: WO2026142290A1
The present invention relates to a biomarker-specific binding probe and a use thereof. By introducing the probe into a nanopore, it is possible to accurately and rapidly detect the presence and abundance of a specific biomarker in a sample.
Resumen de: AU2024388318A1
The present disclosure provides precision medicine or personalized therapy of using a Sigma-1 receptor agonist in treating neurological disease or disorder. The precision medicine or personalized therapy involves patient selection through differentially expressed genes or affected biological pathways related to the Sigma-1 receptor agonist therapy. Also provided are kits for practicing the methods.
Resumen de: US20260185993A1
0000 A functional peptide modified magnetic composite nanobead, and a method and an application thereof for detecting β-secretase (BACE1) and screening its inhibitors are provided. The chemical composition of the magnetic composite nanobead is: ferroferric oxide (Fe<3>O<4>) nanoclusters used as magnetic cores, the surface of the magnetic cores coated with a silica shell, the surface of the shell connected with an ethylene diamine tetraacetic acid (EDTA) modification layer, and Co<2+> or Ni<2+> ions chelated on the EDTA layer, and the Cy5 fluorescein labeled functional peptide coated on the surface of magnetic composite nanobead by the interaction between Co<2+> or Ni<2+> ions and hexahistidine-tag.
Resumen de: WO2026137685A1
The present application relates to the technical field of immunochromatography, and in particular, to a test strip for detecting β-amyloid protein and the use thereof. In the present application, colored microspheres are conjugated to a β-amyloid monoclonal antibody via covalent bonds, and then the conjugate is coated onto a conjugate pad. Compared with colloidal gold, the colored microspheres exhibit greater stability and higher sensitivity. Additionally, the colored microspheres feature bright and diverse colors, uniform particle sizes, good monodispersity, and strong reproducibility of detection results. The test strip provided by the present application has the advantages of simplicity, rapidity and high timeliness, requires no additional reagents, instruments and professional personnel, and supports on-site operation. By means of simply applying a to-be-detected sample to a sample loading port of the test strip, a detection result can be interpreted within 15 min. The result interpretation is visual, intuitive, accurate and straightforward, with a low risk of human errors such as false positives and false negatives.
Resumen de: WO2026137051A1
The present disclosure generally relates to a modified receptor and/or a modified ligand and uses thereof. The modified receptor and/or modified ligand can be used to establish molecular signalling between two biological components, rendering the modified receptor and/or modified ligand suitable in a broad array of applications.
Resumen de: WO2026142751A1
Aspects of the disclosure include methods of treating an autoimmune disease, including reducing the need for chronic immunosuppression, and for effectuating immune reset and/or producing a naive B cell repertoire in a subject in need thereof, the methods comprising administering a therapeutically effective amount of anti-CD20 yδ T cells to the subject, wherein the anti-CD20 yδ T cells express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20.
Resumen de: US20260185138A1
0000 A coupled tethered enzyme luminescence assay for measuring the amount of enzymatic activity of neural specific enolase in a liquid blood sample taken from a patient. The assay has a test well and a positive control well. The test well has a number of components including an inhibitor and a number of first tethered enzyme nanobots formed by tethering pyruvate kinase enzyme to silica nanoparticles, and a number of second enzyme nanobots formed by tethering luciferase molecules to silica nanoparticles for oriented immobilization of the tethered enzymes pyruvate and luciferase. The pyruvate kinase and luciferase enzymes have two differing types of affinity tags. One type of affinity tag facilitates extraction of enzymes from a liquid and another affinity tag for tethering to a silica nanoparticle. The positive control well includes the components of the test well and an added preset amount of enolase enzyme.
Resumen de: US20260183364A1
The present disclosure relates to methods for treating or alleviating a fetal alcohol spectrum disorder (FASD) in a subject, the method comprising administering to the subject an effective amount of an apolipoprotein E (APOE)-modulating therapeutic, thereby treating or alleviating the FASD.
Resumen de: JP2026110170A
【課題】本発明者らは、特に老化組織において炎症を抑制し得る素材をスクリーニングする技術の提供を主な目的とした。【解決手段】上記課題は、工程Ｂ：１５回以上継代された血管内皮細胞に被験物質を接触させる工程、並びに工程Ｃ：ＩＬ－６、ＩＬ－８、ＣＸＣＬ１、ＰＡＩ－１、ＭＭＰ－１、ＩＣＡＭ－１、ＶＣＡＭ－１、Ｅ－ｓｅｌｅｃｔｉｎ、及びＣＣＬ２からなる群より選択される少なくとも１種の炎症関連因子の、工程Ｂで被験物質を接触させた血管内皮細胞における発現量を評価する工程を含む方法により、解決され得る。【選択図】なし
Resumen de: WO2026139512A2
The present invention relates to methods of producing a conformationally constrained peptide in cellulo using a pnictogen-containing crosslinker. The present invention also relates to conformationally constrained peptides obtainable by said methods and a method for screening peptide libraries for transcription factor agonists that tests whether said conformationally constrained peptide inhibits association between two candidate binding partners. The present invention also relates to the use of a pnictogen-containing cross-linker in a method of producing a conformationally constrained peptide in cellulo. The present invention also relates to recombinant peptides comprising three thiol-/selenol-containing residues linked to a pnictogen-containing cross-linker. The present invention also relates to a kit for use in said methods.
Resumen de: WO2026139605A2
The invention relates to biomarkers for mitochondrial disease. Signalling lipids were identified as having good correlations with disease severity. Several of these biomarkers were found to correlate with treatment efficacy. Signalling lipids such as 15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid showed a positive correlation with disease severity and showed a corresponding decrease after treatment of the disease.
Resumen de: WO2026142185A1
In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.
Resumen de: WO2026143158A1
Disclosed herein methods and compositions for diagnosing, stratifying risk, and treating hypoxia-related brain disorders using NHIP genetic variants, DNA methylation signatures, and circulating NHIP peptide levels, as well as NHIP based peptide therapeutics for improving neurological and developmental outcomes.
Resumen de: US20260186004A1
0000 It has been established that increased levels of lactylated of tau protein in the brain and CNS is associated with tauopathies and neurodegenerative diseases, and increased levels of lactylated lysine on tau protein has been established as a marked for AD. Compositions and methods for the detection and treatments of tauopathies have been developed. In some forms, the methods identify and quantify lactylated lysine on tau protein in a biological sample from a subject to diagnose a tauopathy, such as AD. In some forms, the methods identify a subject as having or at risk of having a tauopathy. In some forms, the methods include treating the tauopathy. Compositions to identify a tauopathy include lactylated tau binders, such as antibodies are also described. Compositions to treat or prevent a tauopathy, such as lactylated tau peptides having a defined lactyllysine, are also described.
Resumen de: WO2026141950A1
The present application provides: a spectroscopic analysis substrate for diagnosing dementia, comprising a hydrophilized graphene layer; and a spectroscopic device comprising same. More specifically, the present application provides: a spectroscopic analysis substrate for diagnosing dementia, having improved accuracy due to increased binding force and selectivity for amyloid beta, the substrate comprising a hydrophilized graphene layer; and a spectroscopic device comprising the spectroscopic analysis substrate.
Resumen de: US20260184764A1
0000 The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.
Resumen de: JP2024019568A
To provide enrichment of an antigen-specific antibody for analytical and therapeutic use.SOLUTION: The present invention relates to a method for eliminating the interference described in the specification using particles (e.g., microparticles, nanoparticles; magnetic, non-magnetic) containing surfaces containing the capturing portions described in the specification, or enriching biomarkers, especially antibodies, prior to diagnostic testing, or isolating and using the antibodies for prophylactic or therapeutic purposes. The method described in the specification is a simple, efficient, and cost-effective method for the conditioning of biological samples for managing and mitigating a number of known sample-specific interferences that can lead to erroneous test results and increased risk to patient safety, such as heterophil antibodies in patients treated with monoclonal mouse antibodies or those receiving them for diagnostic purposes.SELECTED DRAWING: None
Resumen de: US20260187803A1
0000 Integrated platforms, systems, and associated processes for measuring lifespan, body size and shape, activity, pathology, pigmentation/color, and multiple in vivo molecular biomarkers using multiple cameras are described. The integrated platform includes a plate and trays supported on the plate. Each tray can hold animals. The integrated platform also includes an imaging module with a first camera and a second camera. The first camera can capture first images associated with movement of the animals and the second camera can capture second images and third images associated with biomarkers of the animals.
Nº publicación: US20260184770A1 02/07/2026
Solicitante:
EISAI R&D MAN CO LTD [JP]
EISAI R&D MANAGEMENT CO., LTD.
Resumen de: US20260184770A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
BOPI
Sede Electrónica
